Open AccessPrognostic role of platelet to lymphocyte ratio in prostate cancer
Author(s) -
Jiangfeng Wang,
Xiaofeng Zhou,
Yuhui He,
Xing Chen,
Naibo Liu,
Zhenshan Ding,
Junjie Li
Publication year - 2018
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000012504
Subject(s) - medicine , meta analysis , prostate cancer , subgroup analysis , oncology , cochrane library , cancer , stage (stratigraphy) , multivariate analysis , lymphocyte , prostate , clinical significance , disease , paleontology , biology
Background: Recently, the prognostic value of the platelet-to-lymphocyte ratio (PLR) has been identified in multiple cancers. However, the prognostic significance of the PLR in prostate cancer (PCa) remains conflicting. We therefore searched relevant studies and conducted a meta-analysis. Methods: Papers from the databases of PubMed, Web of Science, and the Cochrane Library were retrieved. Six studies comprising 1324 patients were included. Results: The pooled analysis demonstrated that an elevated PLR predicted poor overall survival (OS; HR = 1.85, 95% CI = 1.51–2.25, P < .001) and disease-free survival (DFS; HR = 1.4, 95% CI = 1.1–1.79, P = .007). Subgroup analyses showed that the PLR remained a significant prognostic factor for OS irrespective of ethnicity, tumor stage, or cut-off value. The PLR was an indicator of poor DFS in Asian patients, but not in Caucasian patients. No significant publication bias was detected. Conclusion: This meta-analysis showed that a high PLR was correlated with poor DFS and OS in patients with prostate cancer. Due to this meta-analysis being derived from a few studies, the results should be validated in clinical practice.